Shares of Omnicell, Inc. (NASDAQ:OMCL) traded up 2.4% on Monday . The stock traded as high as $77.39 and last traded at $78.66. 9,973 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 283,200 shares. The stock had previously closed at $76.80.
Several analysts have weighed in on the company. Wells Fargo & Co upped their target price on Omnicell from $59.00 to $61.00 and gave the company a “market perform” rating in a report on Monday, October 29th. Zacks Investment Research lowered Omnicell from a “buy” rating to a “hold” rating in a report on Monday, December 31st. BidaskClub raised Omnicell from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $80.00 target price (up previously from $70.00) on shares of Omnicell in a report on Thursday, December 6th. Finally, Piper Jaffray Companies reissued a “neutral” rating and issued a $70.00 target price on shares of Omnicell in a report on Friday. They noted that the move was a valuation call. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $74.88.
The company has a debt-to-equity ratio of 0.20, a current ratio of 1.94 and a quick ratio of 1.45. The company has a market cap of $3.04 billion, a P/E ratio of 52.07, a price-to-earnings-growth ratio of 3.55 and a beta of 1.18.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 7th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.16. The business had revenue of $211.75 million for the quarter, compared to analyst estimates of $215.41 million. Omnicell had a return on equity of 9.31% and a net margin of 4.79%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.55 earnings per share. Research analysts predict that Omnicell, Inc. will post 1.84 earnings per share for the current fiscal year.
In related news, Chairman Randall A. Lipps sold 9,482 shares of the stock in a transaction on Tuesday, December 18th. The stock was sold at an average price of $63.89, for a total transaction of $605,804.98. Following the sale, the chairman now owns 165,025 shares of the company’s stock, valued at $10,543,447.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jorge R. Taborga sold 2,509 shares of the stock in a transaction on Friday, February 1st. The shares were sold at an average price of $64.26, for a total value of $161,228.34. Following the sale, the executive vice president now directly owns 39,262 shares in the company, valued at approximately $2,522,976.12. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,878 shares of company stock worth $2,136,972. Corporate insiders own 3.71% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in shares of Omnicell by 5.9% in the 3rd quarter. BlackRock Inc. now owns 5,903,099 shares of the company’s stock worth $424,432,000 after purchasing an additional 327,747 shares during the period. Vanguard Group Inc. raised its holdings in shares of Omnicell by 27.9% in the 3rd quarter. Vanguard Group Inc. now owns 3,806,211 shares of the company’s stock worth $273,665,000 after purchasing an additional 830,338 shares during the period. Vanguard Group Inc raised its holdings in shares of Omnicell by 27.9% in the 3rd quarter. Vanguard Group Inc now owns 3,806,211 shares of the company’s stock worth $273,665,000 after purchasing an additional 830,338 shares during the period. Conestoga Capital Advisors LLC raised its holdings in shares of Omnicell by 12.4% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 2,060,908 shares of the company’s stock worth $148,179,000 after purchasing an additional 227,685 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of Omnicell by 9.8% in the 3rd quarter. Janus Henderson Group PLC now owns 1,662,720 shares of the company’s stock worth $119,550,000 after purchasing an additional 148,741 shares during the period.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Modern Readers and is the sole property of of Modern Readers. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.modernreaders.com/news/2019/02/11/omnicell-omcl-trading-2-4-higher.html.
About Omnicell (NASDAQ:OMCL)
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Featured Article: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.